26.07.2019 • News • Michael Quirmbach • Corden Pharma • People

Michael Quirmbach Appointed as CEO and President of CordenPharma

CordenPharma has appointed Michael Quirmbach as its new CEO and president, effective Aug. 1, 2019. He is going to succeed Riku Rautsola who will transition to the role of a senior advisor to the executive leadership team.

Quirmbach joined CordenPharma in October 2014 as chief business officer and has been a member of the executive leadership team. Prior to joining CordenPharma, he held several management positions at Siegfried, Dr. Reddy’s and Solvias. Quirmbach holds a degree in chemistry and a PhD from the Max Planck Research Group at the Institute for Organic Catalysis Research in Rostock, Germany, as well as an MBA from La Salle University in Philadelphia, USA.

Free Expert Insights

Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.